Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 12, 2015, Pages 2136-2140

  Chen, Robert ^a   Palmer, Joycelynne M ^a   Martin, Peter ^b   Tsai, Nicole ^a   Kim, Young ^a   Chen, Bihong T ^a   Popplewell, Leslie ^a   Siddiqi, Tanya ^a   Thomas, Sandra H ^a   Mott, Michelle ^a   Sahebi, Firoozeh ^c   Armenian, Saro ^a   Leonard, John ^b   Nademanee, Auayporn ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Autologous hematopoietic transplantation; Brentuximab vedotin; Hodgkin lymphoma; Salvage

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; DRUG SAFETY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; HYPERURICEMIA; HYPOGLYCEMIA; LYMPHOCYTOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRURITUS; RASH; STEM CELL MOBILIZATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; ADOLESCENT; ADULT; AGED; AUTOTRANSPLANTATION; CHILD; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOPENIA; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; HYPERURICEMIA; IMMUNOCONJUGATES; LYMPHOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84947485633     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.018     Document Type: Article

References (20)

1. Cancer facts and figures American Cancer Society, Retrieved from. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index.
2. Connors J.M. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005, 23:6400-6408.
3. Josting A., Rudolph C., Mapara M., et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005, 16:116-123.
4. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616-623.
5. Kuruvilla J., Nagy T., Pintilie M., et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006, 106:353-360.
6. Moskowitz C.H., Bertino J.R., Glassman J.R., et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3776-3785.
7. Bartlett N.L., Niedzwiecki D., Johnson J.L., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007, 18:1071-1079.
8. Francisco J.A., Cerveny C.G., Meyer D.L., et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102:1458-1465.
9. Sutherland M.S., Sanderson R.J., Gordon K.A., et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006, 281:10540-10547.
10. Younes A., Gopal A.K., Smith S.E., et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. J Clin Oncol 2012, 30:2183-2189.
11. de Claro R.A., McGinn K., Kwitkowski V., et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012, 18:5845-5849.
12. Chen R., Palmer J.M., Thomas S.H., et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012, 119:6379-6381.
13. Chen R., Palmer J.M., Tsai N.C., et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2014, 20:1864-1868.
14. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
15. National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 Cancer Therapy Evaluation Program, Retrieved from. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:8.5x11.pdf.
16. Steidl C., Lee T., Shah S.P., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
17. O'Brien C., Cavet G., Pandita A., et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008, 68:5380-5389.
18. Moskowitz A.J., Schoder H., Yahalom J., et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015, 16:284-292.
19. Dumontet C., Duran G.E., Steger K.A., et al. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 1996, 56:1091-1097.
20. Greaves W., Xiao L., Sanchez-Espiridion B., et al. Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol 2012, 5:47.